Roblitinib is an Orally Available Aldehyde Selective for FGFR4
FGF401 (roblitinib)
oral reversible-covalent FGFR4 kinase inhibitor first sel. FGFR4i in clinical studies; for HCC from biochemical HTS and SBDD J. Med. Chem., Oct. 1, 2020 Novartis, Basel, CH
Loading...
